N04 Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NuCana plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$30.00 |
| 52 Week Low | US$1.19 |
| Beta | 1.04 |
| 11 Month Change | -28.31% |
| 3 Month Change | -80.96% |
| 1 Year Change | -87.41% |
| 33 Year Change | -97.98% |
| 5 Year Change | -99.34% |
| Change since IPO | -99.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| N04 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -17.4% | -0.7% | -0.02% |
| 1Y | -87.4% | -17.2% | 8.2% |
Return vs Industry: N04 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: N04 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| N04 volatility | |
|---|---|
| N04 Average Weekly Movement | 57.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: N04's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: N04's weekly volatility has increased from 42% to 58% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 27 | Hugh Griffith | www.nucana.com |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.
NuCana plc Fundamentals Summary
| N04 fundamental statistics | |
|---|---|
| Market cap | €2.65m |
| Earnings (TTM) | -€33.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs N04 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N04 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£28.18m |
| Earnings | -UK£28.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.55 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did N04 perform over the long term?
See historical performance and comparison